Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Short- and Long-Term Mortality and Stroke Risk After Transcatheter Aortic Valve Implantation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Causes of Mortality in the Marfan Syndrome(from a Nationwide Register Study)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Mortality and morbidity of major congenital heart disease related to general prenatal screening for malformations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Long-Term Risk of Infective Endocarditis After Transcatheter Aortic Valve Replacement

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Copenhagen Baby Heart Study: a population study of newborns with prenatal inclusion

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Incidence of infective endocarditis in patients considered at moderate risk

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

No published studies have compared the outcome after transcatheter aortic valve implantation (TAVI) with the outcome in the general population. Thus, it is unknown whether TAVI restores normal life expectancy and stroke risk. Furthermore, despite the increasing use of TAVI, only little is known about the temporal trends for TAVI regarding patient characteristics and outcomes. We identified all Danish patients treated with TAVI from 2006 to 2014 (n = 1,631) and 9,737 general population controls matched by gender, age, and co-morbidity. The primary end point was a composite end point of all-cause mortality and stroke. During the first 90 days, the risk of the combined end point, the stroke risk, and mortality were significantly higher among TAVI patients compared with controls (9.4%, 7.5%, and 2.5%, respectively, in TAVI patients compared with 2.0%, 1.6%, and 0.5% in controls). After 90 days, there were no differences (adjusted mortality rate ratio, stroke rate ratio, and mortality or stroke rate ratio 0.92 [0.79 to 1.06], 1.32 [0.98 to 1.78], and 1.00 [0.90 to 1.10], respectively). During the study period, there were small changes in the characteristics of patients treated with TAVI; however, more patients were treated by transfemoral access; fewer needed blood transfusions, hospital stays were shorter, and the overall mortality rate decreased. In conclusion, 90 days after TAVI, the stroke risk and mortality of the TAVI patients were comparable with the stroke risk and mortality of the general population. Over time, the patient risk profiles have remained largely unchanged; however, outcomes have improved substantially, including lower short- and long-term mortality.

OriginalsprogEngelsk
TidsskriftThe American journal of cardiology
Vol/bind121
Udgave nummer1
Sider (fra-til)78-85
Antal sider8
ISSN0002-9149
DOI
StatusUdgivet - 1 jan. 2018

ID: 52621664